{"entity":{"id":"arcellx","kind":"company","name":"Arcellx","aka":[],"tldr":"Arcellx developed anito-cel, a CAR T-cell therapy for multiple myeloma that reprogrammes a patient's own immune cells to attack a marker called BCMA. Gilead bought the company in 2026 for about $7.8 billion ahead of a possible US approval.","summary":"Arcellx developed anitocabtagene autoleucel (anito-cel), an autologous BCMA-directed CAR T-cell therapy built on the company's synthetic D-domain binder, for relapsed or refractory multiple myeloma. Anito-cel was co-developed and co-commercialised with Kite, a Gilead company, under a 2022 collaboration. The BLA for fourth-line relapsed or refractory multiple myeloma, supported by the phase 1 study (NCT04155749) and the pivotal phase 2 iMMagine-1 study (NCT05396885), was accepted by the FDA with a PDUFA date of 23 December 2026. Arcellx listed on Nasdaq in February 2022 (gross proceeds about $142 million). In February 2026 Gilead agreed to acquire the company for $115 per share in cash plus a $5 contingent value right, an implied equity value of about $7.8 billion, and completed the tender offer and merger on 28 April 2026. Arcellx is now a wholly owned subsidiary of Gilead and arcellx.com redirects to Kite.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.kitepharma.com/"},{"label":"Gilead to acquire Arcellx (February 2026)","url":"https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel"},{"label":"Gilead completes acquisition (April 2026)","url":"https://www.kitepharma.com/news/press-releases/2026/4/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"label":"IPO closing release (8-K, February 2022)","url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker ACLX, delisted after the April 2026 merger. The 2022 IPO release was datelined Gaithersburg, Maryland; the 2026 acquisition release is datelined Redwood City."],"hq":"Redwood City, CA","country":"US","companyType":"cell-therapy","website":"https://www.kitepharma.com/","stage":"acquired","investors":[],"funding":[{"round":"IPO","year":2022,"amountUsd":142300000,"source":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm","note":"9,487,500 shares at $15.00 including full option exercise; Nasdaq ACLX"},{"round":"Acquisition","year":2026,"amountUsd":7800000000,"source":"https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel","note":"$115 per share in cash plus a $5 contingent value right; implied equity value $7.8 billion; completed 28 April 2026"}],"acquiredBy":"gilead"},"route":"/companies/arcellx/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"trial":[{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/"}]}}